Health Canada provides guidance on clinical trial Protocol for planned P3 Clinical Trial Read more…
OPXA presented clinical data highlighting efficacy data from OPXA’s Phase IIb TERMS clinical trial in a sub-population of patients Read more…
OPXA priced an underwritten public offering of 4,146,500 units at a price to the public of $2.05 per unit, for gross proceeds of $8.5M. Read more…
OPXA’s Tovaxin® for multiple sclerosis (MS) completed 2 separate and successfull meetings with the FDA regarding the development program for Tovaxin. Read more…
OPXA reported a net loss of $1.29M or ($0.07) per share. Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.